Consensus of Chinese Experts on the Diagnosis and Treatment of Type Ⅰ Interferonopathy
Type Ⅰ interferonopathy is an autoinflammatory disease that affects multiple systems, with a high disability and mortality rate. It profoundly impacts the quality of life of patients and poses a considerable burden on their families and society. Due to the broad spectrum of clinical phenotypes assoc...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Rare Diseases
2024-10-01
|
| Series: | 罕见病研究 |
| Subjects: | |
| Online Access: | https://jrd.chard.org.cn/article/doi/10.12376/j.issn.2097-0501.2024.04.010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841555694099103744 |
|---|---|
| author | Chinese Alliance of Pediatric Rheumatic & Immunologic Diseases Chinese Pharmacists Association Rare Diseases Medication Working Committee |
| author_facet | Chinese Alliance of Pediatric Rheumatic & Immunologic Diseases Chinese Pharmacists Association Rare Diseases Medication Working Committee |
| author_sort | Chinese Alliance of Pediatric Rheumatic & Immunologic Diseases |
| collection | DOAJ |
| description | Type Ⅰ interferonopathy is an autoinflammatory disease that affects multiple systems, with a high disability and mortality rate. It profoundly impacts the quality of life of patients and poses a considerable burden on their families and society. Due to the broad spectrum of clinical phenotypes associated with this condition, early identification remains challenging. Delays in diagnosis and treatment can exacerbate the disease, making it difficult to reverse the conditions and adversely affecting the prognosis. Therefore, the Chinese Alliance of Pediatric Rheumatic & Immunologic Diseases and Chinese Pharmacists Association Rare Diseases Medication Working Committee has developed this consensus document to offer detailed recommendations pertaining to the definition, genetic categorization, clinical presentations, diagnostic approaches, and therapeutic management of type Ⅰ interferonopathy. |
| format | Article |
| id | doaj-art-a17c85f15ce84c21837a4207ecc144f6 |
| institution | Kabale University |
| issn | 2097-0501 |
| language | zho |
| publishDate | 2024-10-01 |
| publisher | Editorial Office of Journal of Rare Diseases |
| record_format | Article |
| series | 罕见病研究 |
| spelling | doaj-art-a17c85f15ce84c21837a4207ecc144f62025-01-08T05:20:45ZzhoEditorial Office of Journal of Rare Diseases罕见病研究2097-05012024-10-013447147810.12376/j.issn.2097-0501.2024.04.010Consensus of Chinese Experts on the Diagnosis and Treatment of Type Ⅰ InterferonopathyChinese Alliance of Pediatric Rheumatic & Immunologic Diseases0Chinese Pharmacists Association Rare Diseases Medication Working Committee1Department of Pediatric, State Key Laboratory of Complex Severe and Rare Diseases, National Rare Disease Medical Quality Control Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sceiences & Peking Union Medical College, Beijing 100730, ChinaDepartment of Pediatric, State Key Laboratory of Complex Severe and Rare Diseases, National Rare Disease Medical Quality Control Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sceiences & Peking Union Medical College, Beijing 100730, ChinaType Ⅰ interferonopathy is an autoinflammatory disease that affects multiple systems, with a high disability and mortality rate. It profoundly impacts the quality of life of patients and poses a considerable burden on their families and society. Due to the broad spectrum of clinical phenotypes associated with this condition, early identification remains challenging. Delays in diagnosis and treatment can exacerbate the disease, making it difficult to reverse the conditions and adversely affecting the prognosis. Therefore, the Chinese Alliance of Pediatric Rheumatic & Immunologic Diseases and Chinese Pharmacists Association Rare Diseases Medication Working Committee has developed this consensus document to offer detailed recommendations pertaining to the definition, genetic categorization, clinical presentations, diagnostic approaches, and therapeutic management of type Ⅰ interferonopathy.https://jrd.chard.org.cn/article/doi/10.12376/j.issn.2097-0501.2024.04.010type ⅰ interferonopathydiagnosis and treatmentconsensus |
| spellingShingle | Chinese Alliance of Pediatric Rheumatic & Immunologic Diseases Chinese Pharmacists Association Rare Diseases Medication Working Committee Consensus of Chinese Experts on the Diagnosis and Treatment of Type Ⅰ Interferonopathy 罕见病研究 type ⅰ interferonopathy diagnosis and treatment consensus |
| title | Consensus of Chinese Experts on the Diagnosis and Treatment of Type Ⅰ Interferonopathy |
| title_full | Consensus of Chinese Experts on the Diagnosis and Treatment of Type Ⅰ Interferonopathy |
| title_fullStr | Consensus of Chinese Experts on the Diagnosis and Treatment of Type Ⅰ Interferonopathy |
| title_full_unstemmed | Consensus of Chinese Experts on the Diagnosis and Treatment of Type Ⅰ Interferonopathy |
| title_short | Consensus of Chinese Experts on the Diagnosis and Treatment of Type Ⅰ Interferonopathy |
| title_sort | consensus of chinese experts on the diagnosis and treatment of type i interferonopathy |
| topic | type ⅰ interferonopathy diagnosis and treatment consensus |
| url | https://jrd.chard.org.cn/article/doi/10.12376/j.issn.2097-0501.2024.04.010 |
| work_keys_str_mv | AT chineseallianceofpediatricrheumaticimmunologicdiseases consensusofchineseexpertsonthediagnosisandtreatmentoftypeiinterferonopathy AT chinesepharmacistsassociationrarediseasesmedicationworkingcommittee consensusofchineseexpertsonthediagnosisandtreatmentoftypeiinterferonopathy |